Cell Factory Policlinico

Protocolli clinici in corso:

1) Phase I study of intrahepatic reinfusion of highly purified CD133+ stem cells in patients with end stage liver disease. Sponsor: Azienda Ospedaliero-Universitaria di Bologna.
2) Trattamento chirurgico della cardiomiopatia ischemica congestizia con rivascolarizzazione coronarica associata a trapianto di cellule staminali autologhe adulte cd 133+ del midollo osseo. Sponsor: Università di Parma.
3) YNSTEM, INTRAMYOCARDIAL TRANSPLANTATION OF CD 133+ BONE MARROW STEM CELLS IN ADDITION TO CABG SURGERY IN THE ISCHEMIC FAILING HEART. Sponsor: Cardio Centro Ticino, Lugano, Svizzera.

Protocolli clinici in arrivo:

1) Cellule mesenchimali nella paralisi sopranucleare progressiva. Sponsor: Fondazione Grigioni per il morbo di Parkinson
2) REBORNE Ortho 1 trial: Evaluation of efficacy of autologous MSCs combined to biomaterial to enhance bone healing in patients with delayed consolidation after long bone dyaphyseal fracture, requiring graft apposition. Sponsor: Istituti Ortopedici Rizzoli Bologna
3) REBORNE Ortho 2 trial Evaluation of efficacy of autologous MSCs to enhance bone healing in patients with early avascular necrosis of the femoral head. Sponsor Istituti Ortopedici Rizzoli Bologna.
4) REBORNE Ortho 3 trial: Evaluation of efficacy of allogeneic MSCs to enhance bone healing in patients with early avascular necrosis and previous haematologic malignant disease with immunosupression.Sponsor Istituti Ortopedici Rizzoli Bologna
5) REBORNE Maxillo 1: Vertical and sagittal bone augmentation in the maxillar bone and mandible using calcium phosphate granules, membrane and autologous MSCs prior to dental implants. Sponsor Università di Verona.